Search

Your search keyword '"service d'Immunologie"' showing total 18 results
Start Over Author "service d'Immunologie" Journal joint bone spine
18 results on '"service d'Immunologie"'

1. Prealbumin, platelet factor 4 and S100A12 combination at baseline predicts good response to TNF alpha inhibitors in rheumatoid arthritis

Author

Martin Soubrier, Pierre Miossec, Athan Baillet, Jacques Tebib, Hubert Marotte, Olivier Vittecoq, Laurent Grange, Thierry Lequerré, Philippe Gaudin, Thierry Thomas, Candice Trocme, Anaïs Courtier, Xavier Romand, Bertrand Toussaint, Minh Vu Chuong Nguyen, Groupe de Recherche et d'Etude du Processus Inflammatoire (GREPI), VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019]), Université Grenoble Alpes - UFR Médecine (UGA UFRM), Université Grenoble Alpes [2016-2019] (UGA [2016-2019]), INSERM U1059, SAINBIOSE - Santé, Ingénierie, Biologie, Saint-Etienne (SAINBIOSE-ENSMSE), Centre Ingénierie et Santé (CIS-ENSMSE), École des Mines de Saint-Étienne (Mines Saint-Étienne MSE), Institut Mines-Télécom [Paris] (IMT)-Institut Mines-Télécom [Paris] (IMT)-École des Mines de Saint-Étienne (Mines Saint-Étienne MSE), Institut Mines-Télécom [Paris] (IMT)-Institut Mines-Télécom [Paris] (IMT)-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service d'Endocrinologie [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Service de rhumatologie, CHU Clermont-Ferrand, Service d'immunologie et rhumatologie, Hospices Civils de Lyon (HCL)-Hôpital Edouard Herriot [CHU - HCL], Hospices Civils de Lyon (HCL), Thérapeutique Recombinante Expérimentale (TIMC-IMAG-TheREx), Techniques de l'Ingénierie Médicale et de la Complexité - Informatique, Mathématiques et Applications, Grenoble - UMR 5525 (TIMC-IMAG), Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019])-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019]), Service de rhumatologie [CHU Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Physiopathologie, Autoimmunité, maladies Neuromusculaires et THErapies Régénératrices (PANTHER), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), CCSD, Accord Elsevier, Groupe de Recherche et d’Étude du Processus Inflammatoire (GREPI), Université Joseph Fourier - Grenoble 1 (UJF)-EFS, Institut Mines-Télécom [Paris] (IMT)-Institut Mines-Télécom [Paris] (IMT)-Université Jean Monnet [Saint-Étienne] (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM), Groupe de Recherche et d'Etudes du Processus Inflammatoire (GREPI), Université Joseph Fourier - Grenoble 1 (UJF), Université Grenoble Alpes (UGA), Université Joseph Fourier - Grenoble 1 (UJF)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP)-IMAG-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes (UGA)-Université Joseph Fourier - Grenoble 1 (UJF)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP)-IMAG-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes (UGA), Service de rhumatologie [Rouen], Ecologie Comportementale et Biologie des Populations de Poissons (ECOBIOP), and Institut National de la Recherche Agronomique (INRA)-Université de Pau et des Pays de l'Adour (UPPA)

Subjects
Adult, Male, medicine.medical_specialty, [SDV.IMM] Life Sciences [q-bio]/Immunology, [SDV]Life Sciences [q-bio], Platelet Factor 4, Likelihood ratios in diagnostic testing, Gastroenterology, Etanercept, Arthritis, Rheumatoid, Cohort Studies, 03 medical and health sciences, 0302 clinical medicine, Rheumatology, Predictive Value of Tests, Internal medicine, medicine, Adalimumab, Humans, Prealbumin, 030212 general & internal medicine, Prospective Studies, ComputingMilieux_MISCELLANEOUS, 030203 arthritis & rheumatology, Biological Products, biology, business.industry, S100A12 Protein, Middle Aged, medicine.disease, Infliximab, 3. Good health, [SDV] Life Sciences [q-bio], Logistic Models, Treatment Outcome, Rheumatoid arthritis, Antirheumatic Agents, biology.protein, Biomarker (medicine), [SDV.IMM]Life Sciences [q-bio]/Immunology, Apolipoprotein A1, Female, Tumor Necrosis Factor Inhibitors, France, business, Platelet factor 4, Biomarkers, medicine.drug
Abstract

Objectives Tumour necrosis factor-alpha inhibitors (TNFi) are effective treatments for Rheumatoid Arthritis (RA). Responses to treatment are barely predictable. As these treatments are costly and may induce a number of side effects, we aimed at identifying a panel of protein biomarkers that could be used to predict clinical response to TNFi for RA patients. Methods Baseline blood levels of C-reactive protein, platelet factor 4, apolipoprotein A1, prealbumin, α1-antitrypsin, haptoglobin, S100A8/A9 and S100A12 proteins in bDMARD naive patients at the time of TNFi treatment initiation were assessed in a multicentric prospective French cohort. Patients fulfilling good EULAR response at 6 months were considered as responders. Logistic regression was used to determine best biomarker set that could predict good clinical response to TNFi. Results A combination of biomarkers (prealbumin, platelet factor 4 and S100A12) was identified and could predict response to TNFi in RA with sensitivity of 78%, specificity of 77%, positive predictive values (PPV) of 72%, negative predictive values (NPV) of 82%, positive likelihood ratio (LR + ) of 3.35 and negative likelihood ratio (LR−) of 0.28. Lower levels of prealbumin and S100A12 and higher level of platelet factor 4 than the determined cutoff at baseline in RA patients are good predictors for response to TNFi treatment globally as well as to Infliximab, Etanercept and Adalimumab individually. Conclusion A multivariate model combining 3 biomarkers (prealbumin, platelet factor 4 and S100A12) accurately predicted response of RA patients to TNFi and has potential in a daily practice personalized treatment.

Published
2018

2. Familial and syndromic lupus share the same phenotype as other early-onset forms of lupus

Author

François Maurier, Behrouz Kassai, Nicole Fabien, Hélène Lefebvre, Aurélia Carbasse, Maryam Piram, Irène Lemelle, Pauline Soulas-Sprauel, Bruno Ranchin, Hugues Flodrops, Eric Hachulla, Aurélia Lanteri, Brigitte Bader-Meunier, Alexandre Belot, Ulrich Meinzer, Isabelle Rouvet, Stéphane Burtey, Yanick J. Crow, Charlotte Samaille, Héloïse Reumaux, Christophe Malcus, Olivia Weill, Tiphanie Ginhoux, Frédéric Rieux-Laucat, Caroline Galeotti, V. Despert, Anne Pagnier, Isabelle Koné-Paut, Sandrine Morell Dubois, Stéphane Decramer, Service de Pédiatrie - Néphrologie, Médecine interne, Hypertension, Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Service d'immunologie [Centre Hospitalier Lyon Sud - HCL], Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Evaluation et modélisation des effets thérapeutiques, Département biostatistiques et modélisation pour la santé et l'environnement [LBBE], Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 (LBBE), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 (LBBE), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS), EPICIME-CIC 1407 de Lyon, Inserm, Service de Pharmacologie Clinique, hospices civils de Lyon, Centre de Biotechnologie cellulaire, Hospices Civils de Lyon (HCL), Academic Unit of Medical Genetic, University of Manchester [Manchester], Imagine - Institut des maladies génétiques (IMAGINE - U1163), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Immunologie et chimie thérapeutiques (ICT), Cancéropôle du Grand Est-Centre National de la Recherche Scientifique (CNRS), Centre de Référence des Maladies AutoInflammatoires (CeRéMAI), Centre Hospitalier de Versailles André Mignot (CHV), Unité Néphrologie Pédiatrique [CHRU Lille], Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Hôpital Claude Huriez [Lille], CHU Lille, Centre de néphrologie et transplantation rénale [Hôpital de la Conception - APHM], Assistance Publique - Hôpitaux de Marseille (APHM)-Hôpital de la Conception [CHU - APHM] (LA CONCEPTION), Service de médecine interne [hôpitaux privés de Metz], Hôpitaux Privés de Metz (HPMetz), CHU Montpellier, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Service de Pédiatrie [Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), AP-HP Hôpital universitaire Robert-Debré [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service Pédiatrique [Rennes], CHU Pontchaillou [Rennes], Centre Hospitalier Universitaire de La Réunion (CHU La Réunion), Service de Néphrologie Rhumatologie Dermatologie, Hôpital Femme Mère Enfant [CHU - HCL] (HFME), Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL)-HCL Groupement Hospitalier Est-Centre de référence Maladies Rénales Rares, Service de médecine interne [Lille], Service d'immuno-hématologie pédiatrique [CHU Necker], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Necker - Enfants Malades [AP-HP], Department of Pathology, Hôpital Femme-Mère-Enfant, Réponse immunitaire innée dans les maladies infectieuses et auto-immunes – Innate immunity in infectious and autoimmune diseases, Centre International de Recherche en Infectiologie (CIRI), École normale supérieure de Lyon (ENS de Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-École normale supérieure de Lyon (ENS de Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), CHU Toulouse [Toulouse]-Hôpital des Enfants, CHU Toulouse [Toulouse], Centre International de Recherche en Infectiologie - UMR (CIRI), École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre National de la Recherche Scientifique (CNRS)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier de Versailles (CHV), Hôpital Claude Huriez, Université de Lille, Droit et Santé-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Assistance Publique - Hôpitaux de Marseille (APHM)-Hôpital de la Conception [CHU - APHM] (LA CONCEPTION ), HCL Groupement Hospitalier Est-Hôpital Femme Mère Enfant [CHU - HCL] (HFME), Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL)-Centre de référence Maladies Rénales Rares, and Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Necker - Enfants Malades [AP-HP]

Subjects
0301 basic medicine, Male, [SDV]Life Sciences [q-bio], 030232 urology & nephrology, Autoimmunity, Disease, medicine.disease_cause, Pediatrics, Severity of Illness Index, Cohort Studies, 0302 clinical medicine, immune system diseases, Epidemiology, Lupus Erythematosus, Systemic, Monogenic lupus, Age of Onset, skin and connective tissue diseases, Child, Systemic lupus erythematosus, Incidence, Age Factors, Phenotype, 3. Good health, Child, Preschool, Cohort, Disease Progression, [SDV.IMM]Life Sciences [q-bio]/Immunology, Female, medicine.medical_specialty, Adolescent, Risk Assessment, 03 medical and health sciences, Sex Factors, Rheumatology, Internal medicine, medicine, Genetics, Humans, Genetic Predisposition to Disease, Retrospective Studies, business.industry, medicine.disease, 030104 developmental biology, Disease Presentation, Immunology, business, Anti-SSA/Ro autoantibodies, Follow-Up Studies
Abstract

Objective Studies of early-onset systemic lupus erythematosus (SLE) have identified monogenic forms of the disease. The primary objective of this study was to compare the clinical and laboratory features of the first patients included in the GENIAL/LUMUGENE cohort to those reported in previous publications. The secondary objective was to determine whether subgroups with a distinctive pattern of clinical and biological features are seen in predominantly genetic forms of SLE. Methods GENIAL/LUMUGENE is a French nationwide study of the clinical, immunological, and genetic features of juvenile-onset SLE (clinicaltrials.gov # NCT01992666 ). Clinical and laboratory data from the first 64 patients younger than 18 years who were included in the first part of the study were collected retrospectively. Predefined criteria were used to divide the patients into three subgroups: syndromic SLE ( n = 10) and familial SLE ( n = 12) – both presumed to have a strong genetic component – and other forms of early-onset SLE ( n = 42). Results The predefined criteria for identifying subgroups based on knowledge of the clinical and epidemiological features of monogenic SLE showed a significantly younger age at onset in syndromic SLE ( P Conclusions In this study, clinical and epidemiological data alone failed to identify a specific patient subgroup characterized by the same disease presentation or progression. This result may be related to the small sample size or indicate marked heterogeneity of juvenile-onset SLE. Genetic studies using new sequencing techniques in these patients might identify genetic factors responsible for marked phenotypic variability.

Published
2016

3. Indications of glucocorticoids in early arthritis and rheumatoid arthritis: Recommendations for clinical practice based on data from the literature and expert opinion

Author

Thao Pham, Bruno Fautrel, Jean-Francis Maillefert, Emmanuelle Dernis, Thierry Schaeverbeke, Jacques Tebib, Daniel Wendling, Xavier Le Loët, Philippe Gaudin, Alain Cantagrel, Pascal Claudepierre, Gaël Mouterde, Alain Saraux, Adeline Ruyssen-Witrand, Service de rhumatologie [CHU Henri Mondor], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor, Service de rhumatologie, CHU Bordeaux [Bordeaux], Service de Rhumatologie, Université Joseph Fourier - Grenoble 1 (UJF)-CHU Grenoble-Hôpital Michallon, Service de Rhumatologie [Hôpital de la Conception - APHM], Assistance Publique - Hôpitaux de Marseille (APHM)-Hôpital de la Conception [CHU - APHM] (LA CONCEPTION), Service d'immunologie et rhumatologie, Hospices Civils de Lyon (HCL)-Hôpital Edouard Herriot [CHU - HCL], Hospices Civils de Lyon (HCL), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Agents pathogènes et inflammation - UFC (EA 4266) (API), Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Service de rhumatologie [CHU Pitié Salpêtrière] (GRC-08 EEMOIS), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Service de rhumatologie [CHU Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), and Normandie Université (NU)

Subjects
medicine.medical_specialty, Time Factors, Delphi Technique, Health Planning Guidelines, MEDLINE, Delphi method, Alternative medicine, Arthritis, Arthritis, Rheumatoid, 03 medical and health sciences, 0302 clinical medicine, Rheumatology, Internal medicine, medicine, Humans, 030212 general & internal medicine, Glucocorticoids, 030203 arthritis & rheumatology, Evidence-Based Medicine, business.industry, Evidence-based medicine, medicine.disease, Databases, Bibliographic, 3. Good health, [SDV.MHEP.RSOA]Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal system, Rheumatoid arthritis, Practice Guidelines as Topic, Physical therapy, Polyarthritis, business
Abstract

International audience; OBJECTIVE: To develop clinical practice guidelines about the indications of glucocorticoid therapy in early arthritis and established rheumatoid arthritis, based on previously published data and on the opinions of rheumatology experts. METHODS: We used a three-step procedure. (a) A scientific committee used a Delphi procedure to select three questions about glucocorticoid indications: what is the role for glucocorticoid therapy in early arthritis? What is the role for long-term glucocorticoid therapy in established rheumatoid arthritis? What is the role for systemic glucocorticoid therapy in flares of rheumatoid arthritis? (b) Evidence providing answers to the three questions was sought in Pubmed, Embase, Cochrane, and abstracts from the annual meetings of the ACR and EULAR. (c) Based on this evidence, recommendations were developed and validated by a panel of experts. The strength of each recommendation was determined based on the level of the underlying evidence. The level of agreement among experts regarding each recommendation was measured. RESULTS: The literature search retrieved 2851 publications, of which 36 were selected based on the titles and abstracts then on the full-length articles. These 36 studies were presented to the experts as a basis for discussion. Six recommendations rated A to D were developed and validated by the experts. They dealt with the appropriateness of low- or moderate-dose glucocorticoid therapy for a limited period in early polyarthritis after advice from a specialist and in the event of active disease, in combination with disease-modifying antirheumatic drug (DMARD) therapy; the appropriateness of low-dose glucocorticoid therapy (no more than 0.1mg/kg/day) in RA if needed to achieve symptom control; and the appropriateness of oral glucocorticoid therapy (no more than 0.5mg/kg/day) for 1 to 2 weeks in polyarticular flares of RA. CONCLUSION: The six recommendations for everyday practice presented here should help to standardize and to optimize clinical practice, thereby improving the management of patients with early arthritis or RA.

Published
2010

4. Prognosis and follow-up of psoriatic arthritis with peripheral joint involvement: Development of recommendations for clinical practice based on published evidence and expert opinion

Author

Alain Cantagrel, Alain Saraux, Thierry Schaeverbeke, Jacques Tebib, Bernard Combe, Carle Paul, Philippe Gaudin, Philippe Goupille, F. Lavie, Daniel Wendling, Emmanuelle Dernis, Carine Salliot, Jean-Francis Maillefert, René-Marc Flipo, Pascal Claudepierre, Xavier Le Loët, CHU Cochin [APHP], Hôpital Lariboisière, Assistance publique - Hôpitaux de Paris (AP-HP) - Hôpital Lariboisière - Université Paris Diderot - Paris 7 (UP7), Hôpital Henri Mondor, Assistance publique - Hôpitaux de Paris (AP-HP) - Hôpital Henri Mondor - Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Hôpital Pellegrin, CHU Bordeaux [Bordeaux] - Groupe hospitalier Pellegrin, Génétique, Immunothérapie, Chimie et Cancer (GICC), Université François Rabelais - Tours - Centre National de la Recherche Scientifique (CNRS), CHU Grenoble, Université Joseph Fourier - Grenoble 1 (UJF) - CHU Grenoble, CHU Dijon, Centre Hospitalier Universitaire de Dijon (CHU Dijon), Hôpital Lapeyronie, Université Montpellier 1 (UM1) - Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier) - Hôpital Lapeyronie, Service de rhumatologie, Hôpital Bicêtre-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris-Sud - Paris 11 (UP11), Service de rhumatologie [CHU Henri Mondor], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor, CHU Bordeaux [Bordeaux], Service d'immunologie et rhumatologie, Hospices Civils de Lyon (HCL)-Hôpital Edouard Herriot [CHU - HCL], Hospices Civils de Lyon (HCL), Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Service de Rhumatologie, Hôpital Claude Huriez [Lille], CHU Lille-CHU Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Université Joseph Fourier - Grenoble 1 (UJF)-CHU Grenoble-Hôpital Michallon, Service de rhumatologie [CHU Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Agents pathogènes et inflammation - UFC (EA 4266) (API), Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Département de Rhumatologie[Montpellier], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Hôpital Lapeyronie, Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Lariboisière-Fernand-Widal [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), CHU Bordeaux [Bordeaux]-Groupe hospitalier Pellegrin, Génétique, immunothérapie, chimie et cancer (GICC), UMR 6239 CNRS [2008-2011] (GICC UMR 6239 CNRS), Université de Tours (UT)-Centre National de la Recherche Scientifique (CNRS), Université Joseph Fourier - Grenoble 1 (UJF)-CHU Grenoble, Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Hôpital Lapeyronie [Montpellier] (CHU), CHU Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Lariboisière-Université Paris Diderot - Paris 7 (UPD7), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Université de Tours-Centre National de la Recherche Scientifique (CNRS), and Cambefort, Jeanne

Subjects
MESH: Inflammation, [SDV]Life Sciences [q-bio], Delphi method, Alternative medicine, MESH: Monitoring, Physiologic, Arthritis, Recommendations, 0302 clinical medicine, MESH: Arthritis, Psoriatic, 030212 general & internal medicine, Practice Patterns, Physicians', MESH: Publishing, Evidence-Based Medicine, Follow-up, MESH: Follow-Up Studies, Prognosis, MESH: Predictive Value of Tests, 3. Good health, [SDV] Life Sciences [q-bio], MESH: Joints, [SDV.MHEP.RSOA]Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal system, Psoriatic arthritis, Radiological weapon, Predictive value of tests, MESH: Expert Testimony, medicine.medical_specialty, MEDLINE, MESH: Prognosis, 03 medical and health sciences, Rheumatology, Predictive Value of Tests, medicine, Humans, MESH: Physician's Practice Patterns, Expert Testimony, Monitoring, Physiologic, Inflammation, Publishing, 030203 arthritis & rheumatology, MESH: Humans, business.industry, Arthritis, Psoriatic, Everyday clinical practice, Evidence-based medicine, medicine.disease, Radiography, Physical therapy, Joints, business, MESH: Evidence-Based Medicine, Follow-Up Studies
Abstract

International audience; Objectives: To develop recommendations about prognosis and follow-up of psoriatic arthritis (PsA) with peripheral joint involvement in everyday clinical practice. Methods: The strategy was as following: (a) The choice of five questions, by the scientific committee according to the Delphi method, considered as a basis for the recommendations; (b) the Systematic Literature Research based on Medline, Cochrane and abstracts from the annual meetings of SFR, EULAR and ACR. An expert committee composed with 68 rheumatologists elaborated and validated the recommendations, specifying the strength and the degree of agreement for each of them. Results: The questions selected were: (1) How can articular and cutaneous disease activity of PsA be assessed in usual clinical practice? (2) Which parameters are predictive for functional, radiological and fatal outcome in PsA? (3) Which clinical and biological parameters are useful for the follow-up of PsA? At which frequency? (4) Which X-rays are useful for the follow-up of PsA? At which frequency? (5) How can the response to treatments be assessed in PsA? The literature search identified 1181 abstracts and 123 articles were included and analyzed. Seven recommendations, whose strength ranged from B to D, were drafted and validated by a final vote of the expert committee. Conclusion: Seven recommendations about follow-up of patients with PsA for daily practice were developed. They can be expected to improve clinical practice uniformity and, in the longer term, to optimize the management of patients with PsA. (C) 2009 Societe francaise de rhumatologie. Published by Elsevier Masson SAS. All rights reserved.

Published
2009

5. Reply to the comment of Brinster et al. 'Acquired hemophilia, rheumatoid arthritis, and TNFα antagonists'

Author

Gazal, Steven, Sacré, Karim, Allanore, Yannick, Teruel, Maria, Goodall, Alison, Tohma, Shigeto, Alfredsson, Lars, Okada, Yukinori, Xie, Gang, Constantin, Arnaud, Balsa, Alejandro, Kawasaki, Aya, Nicaise, Pascale, Amos, Christopher, Rodríguez-Rodríguez, Luis, Chiocchia, Gilles, Boileau, Catherine, Zhang, Jinyi, Barnetche, Thomas, Gonzalez-Gay, Miguel, Furukawa, Hiroshi, Cantagrel, Alain, Le Loët, Xavier, Sumida, Takayuki, Hurtado-Nedelec, Margarita, Richez, Christophe, Chollet-Martin, Sylvie, Schaeverbeke, Thierry, Combe, Bernard, Khoryati, Liliane, Coustet, Baptiste, El-Benna, Jammel, Siminovitch, Katherine, Plenge, Robert, Padyukov, Leonid, Martin, Javier, Tsuchiya, Naoyuki, Devauchelle-Pensec, Valérie, Gottenberg, Jacques-Eric, Jousse-Joulin, Sandrine, Berthelot, Jean-Marie, Perdriger, Aleth, Hatron, Pierre Yves, Puéchal, Xavier, Le Guern, Véronique, Sibilia, Jean, Chiche, Laurent, Goëb, Vincent, Larroche, Claire, Fauchais, Anne-Laure, Hayem, Gilles, Morel, Jacques, Zarnitsky, Charles, Dubost, Jean Jacques, Dieudé, Philippe, Pers, Jacques Olivier, Cornec, Divi, Seror, Raphaele, Mariette, Xavier, Nowak, Emmanuel, Saraux, Alain, Banse, Christopher, Vittecoq, Olivier, Levesque, Hervé, Université Paris Diderot - Paris 7 (UPD7), Centre de recherche sur l'Inflammation (CRI (UMR_S_1149 / ERL_8252 / U1149)), Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Service de rhumatologie [CHU Cochin], CHU Cochin [AP-HP]-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Spanish National Research Council (CSIC), Department of Cardiovascular Sciences [Leicester], University of Leicester, University of Tsukuba, Centre for Occupational and Environmental Medicine, Stockholm County Council, Broad Institute of MIT and Harvard (BROAD INSTITUTE), Harvard Medical School [Boston] (HMS)-Massachusetts Institute of Technology (MIT)-Massachusetts General Hospital [Boston], University of Toronto, School of Informatics [Edimbourg], University of Edinburgh, University Hospital La Paz, Madrid, Service d'Immunologie, Hôpital Bichat-Claude Bernard, Assistance Publique-Hôpitaux de Paris (AP-HP)-Assistance Publique-Hôpitaux de Paris (AP-HP)-Université Paris Diderot - Paris 7 (UPD7)-PRES Sorbonne Paris Cité, Dartmouth College [Hanover], Rheumatology Service, Hospital Clínico San Carlos, Physiopathologie et Pharmacologie Clinique de la Douleur (LPPD), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de cardiologie, Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-AP-HP - Hôpital Bichat - Claude Bernard [Paris]-Université Paris Diderot - Paris 7 (UPD7), Hôpital Pellegrin, CHU Bordeaux [Bordeaux]-Groupe hospitalier Pellegrin, Kyushu University [Fukuoka], Hôpital Purpan [Toulouse], CHU Toulouse [Toulouse], Protéines de défense des réponses immune et inflammatoire : identification, régulation et rôles physiopathologiques, Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU), Université Paris-Sud - Paris 11 (UP11), Service de rhumatologie, CHU Bordeaux [Bordeaux], Hôpital Lapeyronie [Montpellier] (CHU), Service de Rhumatologie, Département Hospitalo-Universitaire (DHU), Merck & Co. Inc, Karolinska Institutet [Stockholm], Institute of Parasitology and Biomedicine (IPB - GRANADA), Lymphocyte B et Auto-immunité (LBAI), Université de Brest (UBO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Brestois Santé Agro Matière (IBSAM), Université de Brest (UBO), Immuno-Rhumatologie Moléculaire, Université de Strasbourg (UNISTRA)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre hospitalier universitaire de Nantes (CHU Nantes), CHU Pontchaillou [Rennes], Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Institut Cochin (IC UM3 (UMR 8104 / U1016)), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), CHU Saint-Antoine [APHP], Service de rhumatologie [Strasbourg], CHU Strasbourg-Hôpital de Hautepierre [Strasbourg], Hôpital Européen [Fondation Ambroise Paré - Marseille], Service de rhumatologie [Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Internal Medicine, Paris, Service de Médecine interne A et polyclinique médicale [CHU Limoges], CHU Limoges, Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Ambroise Paré, Département de Rhumatologie[Montpellier], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Hôpital Lapeyronie, Service de Rhumatologie - CH Le Havre, CH Le Havre, Département rhumatologie, CHU Clermont-Ferrand, Service de rhumatologie [Bichat], Immunologie et Pathologie (EA2216), Université de Brest (UBO)-IFR148, CHU Cochin [AP-HP], CHU Le Kremlin-Bicêtre (Rheumatology Department), Department of Rheumatology, CIC Brest, Université de Brest (UBO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hôpital de la Cavale Blanche, Institute for Research and Innovation in Biomedicine (IRIB), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Diderot - Paris 7 (UPD7), Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Université de Tsukuba = University of Tsukuba, Université Paris Diderot - Paris 7 (UPD7)-AP-HP - Hôpital Bichat - Claude Bernard [Paris], Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Strasbourg (UNISTRA), CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Service de rhumatologie [CHU Rouen], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Ambroise Paré [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Normandie Université (NU)-Normandie Université (NU)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP], Lymphocytes B, Autoimmunité et Immunothérapies (LBAI), Université de Brest (UBO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-LabEX IGO Immunothérapie Grand Ouest-Institut Brestois Santé Agro Matière (IBSAM), and Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)

Subjects
musculoskeletal diseases, medicine.medical_specialty, congenital, hereditary, and neonatal diseases and abnormalities, Etiology, MESH: Etanercept/adverse effects, [SDV]Life Sciences [q-bio], education, MESH: Arthritis, Rheumatoid/drug therapy, TNFα antagonists, Hemophilia A, Etanercept, Arthritis, Rheumatoid, Rheumatology, hemic and lymphatic diseases, medicine, Humans, MESH: Hemophilia A/chemically induced, Rheumatoid arthritis, skin and connective tissue diseases, MESH: Humans, business.industry, Biotherapy, MESH: Antirheumatic Agents/adverse effects, Joint bone, medicine.disease, Dermatology, Surgery, Acquired hemophilia, Antirheumatic Agents, [SDV.IMM]Life Sciences [q-bio]/Immunology, Tumor necrosis factor alpha, Female, business, MESH: Female
Abstract

Comment on:- Acquired hemophilia possibly induced by etanercept in a patient with rheumatoid arthritis. [Joint Bone Spine. 2015]- Acquired hemophilia, rheumatoid arthritis, and TNFα antagonists: Comment on the article "Acquired hemophilia possibly induced by etanercept in a patient with rheumatoid arthritis" by Banse et al., Joint Bone Spine 2015;82:200-2. [Joint Bone Spine. 2015]; International audience; Correspondance

Published
2015

6. Methotrexate therapy for rheumatoid arthritis: clinical practice guidelines based on published evidence and expert opinion

Author

Thierry Schaeverbeke, Jean Sibilia, Philippe Goupille, Arnaud Constantin, Xavier Mariette, Bernard Combe, Jacques Tebib, Thao Pham, D. Wendling, Xavier Puéchal, René-Marc Flipo, Jean-Francis Maillefert, Stephan Pavy, Maxime Dougados, Laure Gossec, Alain Cantagrel, Xavier Le Loët, Service de Rhumatologie [Hôpital de la Conception - APHM], Assistance Publique - Hôpitaux de Marseille ( APHM ) -Hôpital de la Conception [CHU - APHM] ( LA CONCEPTION ), Modèles et méthodes de l'évaluation thérapeutique des maladies chroniques, Université Paris Diderot - Paris 7 ( UPD7 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Service de rhumatologie [CHU Cochin], Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Cochin [AP-HP], Département de Rhumatologie[Montpellier], Centre Hospitalier Régional Universitaire [Montpellier] ( CHRU Montpellier ) -Hôpital Lapeyronie, Service de Rhumatologie, Hôpital Claude Huriez-Centre Hospitalier Régional Universitaire [Lille] ( CHRU Lille ), Service de rhumatologie, CHRU Tours, Service de rhumatologie [Rouen], CHU Rouen-Université de Rouen Normandie ( UNIROUEN ), Normandie Université ( NU ) -Normandie Université ( NU ), Université Paris-Sud - Paris 11 ( UP11 ) -Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Bicêtre, Service de médecine interne et centre de référence des maladies rares [CHU Cochin], CHU Bordeaux [Bordeaux], Service de rhumatologie [Strasbourg], CHU Strasbourg-Hôpital de Hautepierre [Strasbourg], Service d'immunologie et rhumatologie, Hospices Civils de Lyon ( HCL ) -Hôpital Edouard Herriot [CHU - HCL], Hospices Civils de Lyon ( HCL ), Agents pathogènes et inflammation - UFC (EA 4266) ( API ), Université de Franche-Comté ( UFC ), Assistance Publique - Hôpitaux de Marseille (APHM)-Hôpital de la Conception [CHU - APHM] (LA CONCEPTION), Modèles et méthodes de l'évaluation thérapeutique des maladies chroniques (U738 / UMR_S738), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Diderot - Paris 7 (UPD7), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Hôpital Lapeyronie, Hôpital Claude Huriez [Lille], CHU Lille-CHU Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Service de rhumatologie [CHU Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Hôpital Bicêtre-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris-Sud - Paris 11 (UP11), Hospices Civils de Lyon (HCL)-Hôpital Edouard Herriot [CHU - HCL], Hospices Civils de Lyon (HCL), Agents pathogènes et inflammation - UFC (EA 4266) (API), Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Bicêtre, Hôpital Cochin [AP-HP], and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)

Subjects
MESH : Retrospective Studies, Arthritis, Pulmonary function testing, Arthritis, Rheumatoid, 0302 clinical medicine, MESH: Practice Guidelines as Topic, 030212 general & internal medicine, MESH : Immunosuppressive Agents, MESH: Treatment Outcome, MESH: Arthritis, Rheumatoid, MESH : Evidence-Based Medicine, Evidence-Based Medicine, MESH: Follow-Up Studies, 3. Good health, MESH : Practice Guidelines as Topic, MESH: Methotrexate, Treatment Outcome, [SDV.MHEP.RSOA]Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal system, Rheumatoid arthritis, Practice Guidelines as Topic, MESH: Immunosuppressive Agents, Immunosuppressive Agents, medicine.drug, medicine.medical_specialty, Renal function, MESH : Treatment Outcome, [ SDV.MHEP.RSOA ] Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal system, 03 medical and health sciences, Rheumatology, Internal medicine, medicine, Humans, Retrospective Studies, 030203 arthritis & rheumatology, MESH: Humans, business.industry, MESH : Humans, MESH: Retrospective Studies, MESH : Follow-Up Studies, Evidence-based medicine, medicine.disease, Methotrexate, MESH : Methotrexate, MESH : Arthritis, Rheumatoid, Physical therapy, business, Rheumatism, MESH: Evidence-Based Medicine, Follow-Up Studies
Abstract

International audience; OBJECTIVES: To develop clinical practice guidelines for the use of methotrexate in rheumatoid arthritis (RA), using the evidence-based approach and expert opinion. METHODS: A scientific committee used a Delphi procedure to select five questions, which formed the basis for developing recommendations. Evidence providing answers to the five questions was sought in the Cochrane databases, PubMed, and proceedings of meetings of the French Society for Rheumatology, European League Against Rheumatism, and American College of Rheumatology. Using this evidence, a group of rheumatologists developed and validated the recommendations. For each recommendation, the level of evidence and the extent of agreement among experts were specified. RESULTS: The recommendations were as follows: 1: The starting dosage for methotrexate in patients with RA should not be less than 10 mg/week and should be determined based on disease severity and patient-related factors; 2: When a patient with RA shows an inadequate response to methotrexate, the dosage should be increased at intervals of 6 weeks, up to 20 mg/week, according to tolerance and patient-related factors; 3: When starting methotrexate treatment in a patient with RA, preference should be given to the oral route. A switch to the intramuscular or subcutaneous route should be considered in patients with poor compliance, inadequate effectiveness, or gastrointestinal side effects; 4: At present, there is no evidence indicating that a change in methotrexate dosage is in order when a TNF antagonist is given concomitantly; 5: The investigations that are mandatory before starting methotrexate therapy in a patient with RA consist of a full blood cell count, serum transaminase levels, serum creatinine with computation of creatinine clearance, and a chest radiograph. In addition, serological tests for the hepatitis viruses B and C and a serum albumin assay are recommended. In patients with a history of respiratory disease or current respiratory symptoms, lung function tests with determination of the diffusing capacity for carbon monoxide are recommended; 6: Investigations that are mandatory for monitoring methotrexate therapy in patients with RA consist of full blood cell counts and serum transaminase and creatinine assays. These tests should be obtained at least once a month for the first 3 months then every 4-12 weeks; 7: Folate supplementation can be given routinely to patients treated with methotrexate for RA. In practice, a minimal dosage of 5 mg of folic acid once a week, at a distance from the methotrexate dose, is appropriate; 8: In the event of respiratory symptoms possibly related to methotrexate toxicity, the drug must be stopped and symptom severity evaluated. Should evidence of serious disease be found, the patient should be admitted immediately or advice from a pulmonologist should be obtained immediately. CONCLUSION: Recommendations about methotrexate therapy for RA were developed. These recommendations should help to improve practice uniformity and, ultimately, to improve the management of RA.

Published
2006

7. Pathogenic effects of anti-citrullinated protein antibodies in rheumatoid arthritis - role for glycosylation.

Author

Coutant F

Subjects
Anti-Citrullinated Protein Antibodies metabolism, Arthritis, Rheumatoid metabolism, Biomarkers metabolism, Glycosylation, Humans, Anti-Citrullinated Protein Antibodies immunology, Arthritis, Rheumatoid immunology, Autoantibodies immunology, Autoimmunity
Abstract

The identification in 1998 of the main antigenic substrate recognized by autoantibodies was a dramatic turning point in our understanding of rheumatoid arthritis (RA) biology. Now, two decades later, antibodies to citrullinated proteins are viewed no longer as mere biomarkers for RA, but also as major pathophysiological factors involved in the development of bone loss and joint pain. These pathogenic effects are ascribable to abnormal autoantibody glycosylation via a pathway involving the Th17T cells. In the future, abnormal autoantibody glycosylation may serve as a disease activity biomarker and suggest novel treatment strategies., (Copyright © 2019 Société française de rhumatologie. Published by Elsevier Masson SAS. All rights reserved.)

Published
2019
Full Text
View/download PDF

8. Rare diseases that mimic Systemic Lupus Erythematosus (Lupus mimickers).

Author

Chasset F, Richez C, Martin T, Belot A, Korganow AS, and Arnaud L

Subjects
Anemia, Hemolytic, Autoimmune epidemiology, Antibodies, Antinuclear immunology, Autoimmune Diseases epidemiology, Castleman Disease epidemiology, Diagnosis, Differential, Female, Histiocytic Necrotizing Lymphadenitis diagnosis, Histiocytic Necrotizing Lymphadenitis epidemiology, Humans, Incidence, Lupus Erythematosus, Systemic epidemiology, Lupus Erythematosus, Systemic immunology, Male, Rare Diseases epidemiology, Risk Assessment, Thrombocytopenia epidemiology, Anemia, Hemolytic, Autoimmune diagnosis, Antibodies, Antinuclear analysis, Autoimmune Diseases diagnosis, Castleman Disease diagnosis, Lupus Erythematosus, Systemic diagnosis, Rare Diseases diagnosis, Thrombocytopenia diagnosis
Abstract

Several conditions have clinical and laboratory features that can mimic those present in Systemic Lupus Erythematosus (SLE). Some of these "SLE mimickers" are very common, such as rosacea which can be mistaken for the butterfly rash, while others such as Kikuchi disease, type-1 interferonopathies, Castleman's disease, prolidase deficiency, angioimmunoblastic T-cell lymphoma, Evans' syndrome in the context of primary immune deficiencies and the autoimmune lymphoproliferative syndrome are exceptionally uncommon. A proper diagnosis of SLE must therefore be based upon a complete medical history as well as on the adequate constellation of clinical or laboratory findings. While there is no single test that determines whether a patient has lupus or not, the search for auto-antibodies towards nuclear antigens is a key step in the diagnosis strategy, keeping in mind that ANAs are not specific for SLE. In case of persistent doubt, patients should be referred to reference centers with experience in the management of the disease., (Copyright © 2018. Published by Elsevier Masson SAS.)

Published
2019
Full Text
View/download PDF

9. Anti-citrullinated peptides antibodies in systemic sclerosis: Meta-analysis of frequency and meaning.

Author

Laustriat G, Ruyssen-Witrand A, Constantin A, Barnetche T, Adoue D, Cantagrel A, and Degboé Y

Subjects
Anti-Citrullinated Protein Antibodies immunology, Biomarkers metabolism, Female, Humans, Male, Prevalence, Risk Assessment, Scleroderma, Systemic metabolism, Sensitivity and Specificity, Severity of Illness Index, Anti-Citrullinated Protein Antibodies metabolism, Disease Progression, Scleroderma, Systemic immunology, Scleroderma, Systemic physiopathology
Abstract

Objectives: Diagnosis of systemic sclerosis (SSc) is partially determined by the presence of specific autoantibodies often associated with specific clinical features. Recent studies report the presence of ACPA in SSc. We aimed to evaluate the prevalence of ACPA in SSc and to assess their influence on clinical presentation of SSc., Methods: A systematic literature search was performed using PubMed and Cochrane databases' publications between 1999 and March 2017. Search terms were: "systemic sclerosis [MeSH] AND (ACPA OR anti-CCP OR rheumatoid factor OR cohort OR value diagnostic)". In a first step, we selected cohorts with >50 SSc patients with ACPA identification, for ACPA frequency determination. In a second step, we included studies that analysed clinical profiles according to ACPA status. Meta-analyses were performed when at least two studies were available., Results: First, we identified 13 observational studies with a total of 1231 SSc patients. The mean prevalence of ACPA in SSc was 9.2%. Secondly, we identified nine studies reporting clinical aspects according to ACPA status. Our meta-analyses showed a significant association between ACPA positivity and the presence of arthritis (odds ratio (OR)=22.48 [10.71-47.21]), joint erosions seen on X-rays (OR=14.79 [6.38-34.28]), pulmonary fibrosis (OR=2.75 [1.21-6.24]), oesophagus involvement (OR=2.72 [1.05-7.07]), and diffuse skin involvement (OR=2.21 [1.21-4.03])., Conclusions: The prevalence of ACPA in scleroderma is 9.2%. Our meta-analysis shows an increased risk for erosive arthritis, pulmonary fibrosis, oesophagus involvement and diffuse skin involvement, in patients with ACPA-positive SSc. ACPA should be systematically included in SSc assessment., (Copyright © 2017 Société française de rhumatologie. Published by Elsevier SAS. All rights reserved.)

Published
2018
Full Text
View/download PDF

10. Inflammatory myopathies: A new landscape.

Author

Meyer A, Lannes B, Goetz J, Echaniz-Laguna A, Lipsker D, Arnaud L, Martin T, Gottenberg JE, Geny B, and Sibilia J

Subjects
Biopsy, Humans, Myositis pathology, Myositis therapy, Autoantibodies, Autoimmune Diseases immunology, Immunologic Factors therapeutic use, Immunomodulation immunology, Muscle, Skeletal pathology, Myositis immunology
Abstract

Greater accuracy in clinical descriptions combined with advances in muscle histology and immunology have established that inflammatory myopathies (IMs), similarly to inflammatory rheumatic diseases, constitute a highly heterogeneous group of conditions. The topographic distribution, severity, and tempo of onset of the myopathy vary widely, and the histological findings distinguish at least five different profiles, which may reflect different pathophysiological processes. Most IMs are connective tissue diseases that can affect multiple organs, among which the most common targets are the skin, joints, and lungs. The extramuscular manifestations may antedate the muscular involvement and should therefore suggest a diagnosis of IM even in the absence of obvious muscle disease. About 20 different autoantibodies have been identified in patients with IM. Some are mutually exclusive and associated with specific combinations of clinical manifestations. Following the model of antisynthetase syndrome, about 10 syndromes associated with autoantibodies specific of IM have been identified. Thus, polymyositis is now emerging as a rare entity that is often mistaken for more recently described patterns of IM. No consensus exists to date about the classification of IMs. Nevertheless, the clinical manifestations, autoantibody profile, and muscle histology can be used to distinguish patient subgroups with fairly homogeneous patterns of complications, treatment responses, and outcomes. These subgroups are also characterized by specific genetic and environmental factors. The advances made in the nosology of IMs have benefited the diagnosis, personalization of treatment strategies, and understanding of pathophysiological mechanisms. They can be expected to assist in the development of specific treatments., (Copyright © 2017 Société française de rhumatologie. Published by Elsevier SAS. All rights reserved.)

Published
2018
Full Text
View/download PDF

11. Familial and syndromic lupus share the same phenotype as other early-onset forms of lupus.

Author

Weill O, Decramer S, Malcus C, Kassai B, Rouvet I, Ginhoux T, Crow YJ, Rieux-Laucat F, Soulas-Sprauel P, Pagnier A, Koné-Paut I, Piram M, Galeotti C, Samaille C, Reumaux H, Lanteri A, Dubois SM, Lefebvre H, Burtey S, Maurier F, Carbasse A, Lemelle I, Meinzer U, Despert V, Flodrops H, Fabien N, Ranchin B, Hachulla E, Bader-Meunier B, and Belot A

Subjects
Adolescent, Age Factors, Age of Onset, Child, Child, Preschool, Cohort Studies, Disease Progression, Female, Follow-Up Studies, Humans, Incidence, Lupus Erythematosus, Systemic epidemiology, Male, Retrospective Studies, Risk Assessment, Severity of Illness Index, Sex Factors, Genetic Predisposition to Disease epidemiology, Lupus Erythematosus, Systemic diagnosis, Lupus Erythematosus, Systemic genetics, Phenotype
Abstract

Objective: Studies of early-onset systemic lupus erythematosus (SLE) have identified monogenic forms of the disease. The primary objective of this study was to compare the clinical and laboratory features of the first patients included in the GENIAL/LUMUGENE cohort to those reported in previous publications. The secondary objective was to determine whether subgroups with a distinctive pattern of clinical and biological features are seen in predominantly genetic forms of SLE., Methods: GENIAL/LUMUGENE is a French nationwide study of the clinical, immunological, and genetic features of juvenile-onset SLE (clinicaltrials.gov #NCT01992666). Clinical and laboratory data from the first 64 patients younger than 18 years who were included in the first part of the study were collected retrospectively. Predefined criteria were used to divide the patients into three subgroups: syndromic SLE (n=10) and familial SLE (n=12) - both presumed to have a strong genetic component - and other forms of early-onset SLE (n=42)., Results: The predefined criteria for identifying subgroups based on knowledge of the clinical and epidemiological features of monogenic SLE showed a significantly younger age at onset in syndromic SLE (P<0.05) and a lower frequency of joint manifestations in familial SLE., Conclusions: In this study, clinical and epidemiological data alone failed to identify a specific patient subgroup characterized by the same disease presentation or progression. This result may be related to the small sample size or indicate marked heterogeneity of juvenile-onset SLE. Genetic studies using new sequencing techniques in these patients might identify genetic factors responsible for marked phenotypic variability., (Copyright © 2016. Published by Elsevier SAS.)

Published
2017
Full Text
View/download PDF

12. Anti-Saccharomyces cerevisiae antibodies (ASCA) in spondyloarthritis: Prevalence and associated phenotype.

Author

Maillet J, Ottaviani S, Tubach F, Roy C, Nicaise-Rolland P, Palazzo E, and Dieudé P

Subjects
Adult, Age Factors, Analysis of Variance, Biomarkers analysis, Case-Control Studies, Confidence Intervals, Databases, Factual, Female, Humans, Male, Middle Aged, Odds Ratio, Phenotype, Prognosis, Reference Values, Risk Assessment, Severity of Illness Index, Spondylarthritis epidemiology, Spondylarthritis genetics, Antibodies, Anti-Idiotypic analysis, Antibodies, Anti-Idiotypic immunology, Saccharomyces cerevisiae immunology, Spondylarthritis immunology
Abstract

Objective: The aim of the study was to compare the prevalence of ASCA in spondyloarthrites (SpA) patients and to investigate the association between ASCA status and disease phenotype., Methods: We performed a case-control study including SpA individuals fulfilling the ESSG SpA criteria. The following data were collected for analysis: gender, age, disease duration, clinical or associated features of SpA, treatments, HLAB27 and ASCA status. A control group of patients without SpA was also analyzed., Results: A total of 235 patients with SpA and 54 control patients were studied. The median age of SpA patients (53.6% of male patients, 52.2% of HLAB27) was 46.0 [IQR 35.0-57.0] years old. Disease duration was 60.0 [IQR 24.0-156.0] months. Inflammatory bowel diseases were observed in 11% of SpA patients. ASCA positivity was significantly higher in SpA patients than in control patients (25.5% [95% CI 20.1-31.6] (IgG: 9.8%; IgA: 21.7%) vs. 7.4% [95% CI 2.1-17.9], P=0.004). Multivariate analysis revealed that ASCA positivity was associated with peripheral involvement (OR: 3.30 [1.26-8.62], P=0.015), presence of IBD (OR: 3.43 [1.15-10.20], P=0.026), past of present history of uveitis (OR: 4.36 [1.08-17.64], P=0.039) and arthritis (OR: 3.78 [1.57-9.15], P=0.003)., Conclusion: Our results provided evidence that SpA patients had an increased prevalence of ASCA and that ASCA positivity might be associated with a particular phenotype, notably peripheral involvement and uveitis., (Copyright © 2016. Published by Elsevier SAS.)

Published
2016
Full Text
View/download PDF

13. Effect of serum anti-tumour necrosis factor (TNF) drug trough concentrations and antidrug antibodies (ADAb) to further anti-TNF short-term effectiveness after switching in rheumatoid arthritis and axial spondyloarthritis.

Author

Vincent FB, Pavy S, Krzysiek R, Lequerré T, Sellam J, Taoufik Y, Mariette X, and Miceli-Richard C

Subjects
Adalimumab blood, Adalimumab immunology, Adalimumab therapeutic use, Adult, Aged, Antibodies, Antirheumatic Agents blood, Antirheumatic Agents therapeutic use, Arthritis, Rheumatoid blood, Biomarkers, Etanercept blood, Etanercept immunology, Etanercept therapeutic use, Female, Humans, Infliximab blood, Infliximab immunology, Infliximab therapeutic use, Male, Middle Aged, Prospective Studies, Spondylarthritis blood, Tumor Necrosis Factor-alpha antagonists & inhibitors, Tumor Necrosis Factor-alpha immunology, Antirheumatic Agents immunology, Arthritis, Rheumatoid drug therapy, Arthritis, Rheumatoid immunology, Drug Tolerance immunology, Spondylarthritis drug therapy, Spondylarthritis immunology
Published
2016
Full Text
View/download PDF

14. Long-term safety of tocilizumab treatment on chronic active hepatitis C in a patient with adult onset Still's disease.

Author

Forestier E and Pasquali JL

Subjects
Adult, Female, Glucocorticoids therapeutic use, Hepatitis C, Chronic drug therapy, Humans, Still's Disease, Adult-Onset complications, Time Factors, Treatment Outcome, Antibodies, Monoclonal, Humanized therapeutic use, Antirheumatic Agents therapeutic use, Hepatitis C, Chronic complications, Still's Disease, Adult-Onset drug therapy
Published
2015
Full Text
View/download PDF

15. High anti-CCP antibody titres predict good response to rituximab in patients with active rheumatoid arthritis.

Author

Gardette A, Ottaviani S, Tubach F, Roy C, Nicaise-Roland P, Palazzo E, Gill G, Meyer O, and Dieudé P

Subjects
Arthritis, Rheumatoid blood, Arthritis, Rheumatoid immunology, Biomarkers blood, Biomarkers urine, Female, Humans, Male, Middle Aged, Peptides, Cyclic blood, Retrospective Studies, Rituximab, Antibodies, Monoclonal, Murine-Derived therapeutic use, Antirheumatic Agents therapeutic use, Arthritis, Rheumatoid drug therapy, Peptides, Cyclic immunology
Abstract

Objective: Previous studies reported that anti-CCP antibody positivity predicts good response to rituximab (RTX) in rheumatoid arthritis (RA). A quantitative approach to such possibility could be a good way to detect the subset of patients most likely to respond. We investigated whether serum anti-CCP antibody titres could predict response to RTX in RA patients., Methods: We retrospectively investigated RA patients who received RTX. The primary criterion was decrease in DAS28>1.2 at 6months (M6). Secondary efficacy criteria included a good response and remission according to EULAR. Predictors of response were investigated by multivariate logistic regression analysis., Results: We included 114 RA patients (81.6% female, median age 53.5 [IQR 45.7-61.2] years, median disease duration 8.5 [4.0-16.0] years). Anti-CCP antibodies were present in 93 patients (81.6%), with median anti-CCP antibody titres 583 [195-1509] U/mL. In all, 44 patients (38.6%) showed decreased DAS28>1.2 at M6. On univariate analysis, high anti-CCP titres were associated with response rather than non-response to RTX (median 1122 [355-1755] vs. 386 [149-800] U/mL, P=0.0191) at M6. On multivariate regression analysis, with a cut-off of 1000 U/mL, anti-CCP antibody titres≥1000 was associated with a decrease in DAS28>1.2 (OR 5.10 [1.97-13.2], P=0.0002); a EULAR good response (4.26 [1.52-11.95], P=0.0059); and a trend for EULAR remission (2.52 [0.78-8.12], P=0.1207)., Conclusion: High anti-CCP antibody titres predict response to RTX in RA. This factor, easily assessed in clinical practice, can help with personalized medicine and selecting the best candidates for RTX treatment., (Copyright © 2014 Société française de rhumatologie. Published by Elsevier SAS. All rights reserved.)

Published
2014
Full Text
View/download PDF

16. HTLV-1-associated arthropathy treated with anti-TNF-alpha agent.

Author

Frenzel L, Moura B, Marcais A, Chapdelaine H, and Hermine O

Subjects
Arthritis, Infectious diagnostic imaging, Arthritis, Infectious virology, Etanercept, Female, Humans, Middle Aged, Radiography, Antirheumatic Agents therapeutic use, Arthritis, Infectious drug therapy, Human T-lymphotropic virus 1, Immunoglobulin G therapeutic use, Receptors, Tumor Necrosis Factor therapeutic use, Tumor Necrosis Factor-alpha antagonists & inhibitors
Abstract

Human T cell leukemia virus type 1 or HTLV-1 infection is a public health problem in endemic regions like Japan, Central America or Africa. Although the majority of HTLV-1 carriers remain asymptomatic throughout their lives, some patients could develop neurological disorder, inflammatory arthropathy also called HTLV-1-associated arthropathy or T-cell malignancy, the adult T-cell leukemia/lymphoma or ATL with a very poor prognosis. Described to be very close to rheumatoid arthritis, HTLV-1-associated arthropathy patients have few or no response to the first line therapy with corticosteroids and disease modifying antirheumatic drugs or DMARDs. The use of anti-TNF-α agents in these patients is an interesting alternative but asks the question of risk of developing an adult T-Cell leukemia/lymphoma. We reported an exceptional case of a smoldering ATL patient with an HTLV-1-associated arthropathy, refractory to corticosteroid, DMARDs and rituximab therapy, treated successfully with etanercept, without progression to aggressive ATL after 5 years., (Copyright © 2013 Société française de rhumatologie. Published by Elsevier SAS. All rights reserved.)

Published
2014
Full Text
View/download PDF

17. An arthro-dermato-pulmonary syndrome associated with anti-MDA5 antibodies.

Author

Goussot R, Theulin A, Goetz J, Sibilia J, Gottenberg JE, and Meyer A

Subjects
Antibodies, Anti-Idiotypic, Arthritis immunology, DEAD-box RNA Helicases antagonists & inhibitors, Dermatomyositis complications, Female, Humans, Interferon-Induced Helicase, IFIH1, Middle Aged, Syndrome, DEAD-box RNA Helicases immunology, Dermatomyositis diagnosis, Dermatomyositis immunology
Published
2014
Full Text
View/download PDF

18. A severe Whipple disease with an immune reconstitution inflammatory syndrome: an additional case of thalidomide efficiency.

Author

Le Blay P, Rakotonirainy H, Lagier JC, Raoult D, Puechal X, and Pers YM

Subjects
Adult, Humans, Immune Reconstitution Inflammatory Syndrome immunology, Male, Whipple Disease immunology, Immune Reconstitution Inflammatory Syndrome drug therapy, Immunosuppressive Agents therapeutic use, Thalidomide therapeutic use, Whipple Disease complications
Abstract

We report the case of a 38-year-old man who presented with severe diarrhea, weight loss of 10 kg, ankles paresthesia and severe motor weakness in the left fibular nerve territory after introduction of azathioprine and corticosteroid for proteinuria. Coloscopy and gastroscopy revealed a typical aspect of Whipple disease (WD), associated with both positive PAS staining and specific immunohistochemistry. T. whipplei PCR results were positive in blood, faeces, saliva and duodenal biopsy specimens. Diagnosis of WD with systemic manifestations was retained and doxycycline plus hydroxychloroquine therapy were started. This treatment improved joint pain, and skin and intestinal symptoms. One month later, our patient presented with fever and an important inflammatory syndrome (CRP 150 mg/dL and 16.8 10(9)/L leukocytes), while no infection was found despite a thorough review. We concluded it was an immune reconstitution inflammatory syndrome (IRIS). Manifestations persisted despite increasing corticosteroids and thalidomide (200 mg/day) was introduced with good efficacy on these symptoms. WD may be revealed by non-specific symptoms such as weight loss or arthralgia, but also by many other misleading signs. Our observation illustrates the highly polymorphic clinical presentation of WD, and the diagnostic difficulties that may arise. This is also a new report of thalidomide effectiveness in IRIS in WD., (Copyright © 2013 Société française de rhumatologie. Published by Elsevier SAS. All rights reserved.)

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results